Packaging, Shipping and Delivery. SUPPLIER is responsible for all containers, preparation, labeling, packaging, country-of-origin marking, loading and handling (“Shipment Preparation”). All Shipment Preparation shall be in such a manner as to reasonably ensure transportation without damage, and be in accordance with specifications provided by BUYER and applicable law and standards for international shipments by sea. Shipping instructions for the Products shall be provided by BUYER and shall designate a carrier, destination, which may be a BUYER factory or warehouse, third-party warehouse facility, contracted dealer or distributor, or any combination of the above. All shipments shall be FOB pursuant to INCOTERMS 2000 of the International Chamber of Commerce. Bills of Lading, packing lists and other shipping documents specified by BUYER shall be forwarded to BUYER or BUYER’s freight forwarder as instructed by BUYER. SUPPLIER, at SUPPLIER’s expense, shall obtain all export licenses and export customs clearances for the Products necessary to ship the Products from Korea within the timeframes set forth in this Agreement.
Packaging, Shipping and Delivery. Peak shall ship the Products in accordance with packaging and shipping instructions provided by Aksys. Unless otherwise specified in writing in a particular PO release, all Product deliveries shall be shipped F.O.B. factory to the destination specified by Aksys for delivery, and Peak shall insure such shipments against any loss or damage to the goods caused during shipment.
Packaging, Shipping and Delivery. The Marketing Agent shall be responsible for the instructing and training of Owner's employees who will physically be responsible for the proper packaging of the Product. Marketing Agent shall be responsible for all shipping and delivery arrangements for the Product, at owner's sole expense.
Packaging, Shipping and Delivery. All packaging and shipping memoranda must bear this ORDER NUMBER. Packaging, etc., must be PLAINLY MARKED and accompanied by a shipping memorandum specifying: A. Goods and Quantities in each container. B. Material Number and Revision Level. C. Certificate of Compliance (as required) which will accurately reflect materials, methods of construction and other manufacturing aspects as may be so specified on the Certificate. Packages must show gross, tare and net weights and/or quantity. The Seller, or carrier it uses to transport the items on this order, whichever is applicable, shall maintain a satisfactory safety rating from the U.S.
Packaging, Shipping and Delivery. GSK will fill, release, package and label such Clinical Trial Materials in final bottles or blisters (one dose per package or such other dose per package as agreed by the Joint Project Team to complete the Development Plan) using due care and in accordance with Applicable Laws and any specifications as the Parties may agree in writing. POZEN will be responsible for identification testing, randomization and clinical patient labeling of Clinical Trial Material supplied to POZEN in the final packaging. POZEN will complete such identification testing, randomization, and clinical patient labeling of Clinical Trial Materials as soon as practicable using Commercially Reasonable Efforts following receipt of the Clinical Trial Materials from GSK. GSK will ship the Clinical Trial Materials [* *] (Incoterms 2000) to the facility as POZEN may designate to GSK by a common carrier designated by POZEN. Each shipment will be made generally in accordance with the Formulation Development Timeline and under the terms and conditions set forth in this Section 3.6 and the Development Plan. Each shipment will include (i) a certificate of analysis and any other release data customarily transferred by GSK in accordance with its usual practice. The remaining shelf life upon delivery will be not less than [* *] for Clinical Trial Materials. GSK will notify POZEN of the results of ongoing stability testing of the Clinical Trial Material by GSK.
Packaging, Shipping and Delivery. Deliveries of all material, including documentation, returned consumable items or Equipment under Clauses 3.2 or 3.3, and API will be made Ex Works, Avecia’s Billingham facility (Incoterms 2000), subject to the following. Avecia is responsible for packaging and labelling the API in anticipation of shipment. Avecia also shall employ a shipper, reasonably acceptable to Nuvelo, for the shipment of all Released API and any Defective Batch. Avecia will package the Released API or Defective Batch in validated containers under validated shipping conditions. Until the shipping conditions have been validated, Avecia will package the Released API or Defective Batch with temperature monitoring devices that are able to function properly during the shipping process, as further set forth in the Quality Agreement. Risk of loss for all Released API or Defective Batch shall transfer to Nuvelo after delivery of the Released API or Defective Batch to the Nuvelo-approved shipper by Avecia, except with respect to any loss resulting from a failure of Avecia to properly package and label the API for shipment. Nuvelo will purchase insurance to cover any loss to the Released API or Defective Batch once it is delivered to the shipper. Nuvelo agrees that it shall export the API sold to it promptly and in any case within 3 months of the final stage payment for the API and shall provide evidence of such export within 3 months thereof.
Packaging, Shipping and Delivery. LSO shall ship the Buyer’s Products in accordance with packaging and shipping instructions provided by Buyer. Unless otherwise specified in writing in a particular Order, all Product deliveries shall be shipped F.O.B. destination.
Packaging, Shipping and Delivery. The Supplier shall ship the Products in accordance with the Specifications and any other packaging, labeling, and shipping instructions provided by SSI. Unless otherwise specified in the Purchase Order, all Product deliveries shall be shipped F.C.A. (Incoterms 2000) the Supplier’s shipping point to the destination specified by SSI for delivery, and the Supplier shall (at SSI’s request and reasonable expense) insure such shipments against any loss or damage to the goods caused during shipment. The Supplier shall not be liable for any costs or expenses, which might be incurred by SSI as a result of any delays in delivery by the shipper, unless caused by the negligence, intentional misconduct, or failure to adhere to the Specifications or SSI’s other shipping instructions of the Supplier or on the Supplier’s behalf. Title and risk of loss to the Products shall pass to SSI upon the Supplier’s delivery to the shipper.
Packaging, Shipping and Delivery. MedImmune will fill, release, package and label Clinical Trial Materials for shipment using due care and in accordance with Applicable Laws and the specifications set forth in the Development Plan. Any packaging and labeling material for such Clinical Trial Materials to be used in countries outside the Territory will be provided by Micromet, at the cost and expense of Micromet. MedImmune will ship such Clinical Trial Materials [***] (Incoterms 2000) MedImmune’s facility by a common carrier designated by Micromet in the applicable purchase order. Each shipment will be made according to the delivery schedule and in the amounts specified in the applicable purchase order, *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. and under the terms and conditions set forth in this Agreement. Each shipment will include a certificate of analysis and such other documentation as may be requested on the applicable purchase order.
Packaging, Shipping and Delivery. MedImmune will ship the Clinical Materials [***] (Incoterms 2000) [***] facility by a common carrier designated by Micromet. Each shipment will be made under the terms and conditions set forth in this Agreement. Each shipment will include a certificate of analysis and a certificate of compliance and will be released by MedImmune Pharma BV’s qualified person for import, labeling and distribution to clinical trial sites.
